|
1) Jones D. Nephrotic glomerulonephritis. Am J Pathol. 1957; 33: 313-30
|
|
|
|
2) Cattran D. Management of membranous nephropathy: When and what for treatment. J Am Soc Nephrol. 2005; 16: 1188-94
|
|
|
|
|
3) 堺 秀人, 黒川 清, 斉藤喬雄, 他. 難治性ネフロ-ゼ症候群(成人例)の診療指針. 日腎会誌. 2002; 44: 751-61
|
|
|
|
|
4) Shiiki H, Saito T, Nishitani Y, et al. Prognosis and risk factors for idiopathic membranous nephropathy with nephrotic syndrome in Japan. Kidney Int. 2004; 65: 1400-7
|
|
|
|
|
|
5) Ronco P, Debiec H. Target antigens and nephritogenic antibodies in membranous nephropathy: of rats and men. Semin Immunopathol. 2007; 29: 445-58
|
|
|
|
|
|
6) Beck LH, Bonegio RGB, Lambeau G, et al. M-type phospholipase A2 receptor as target antigen in idiopathic membranous nephropathy. N Engl J Med. 2009; 361: 11-21
|
|
|
|
|
|
7) Heymann W, Hackel DB, Harwood S, et al. Production of nephrotic syndrome in rats by Freund's adjuvant and rat kidney suspensions. Proc Soc Exp Biol Med. 1959; 100: 660-4
|
|
|
|
|
|
8) Cybulsky AV, Quigg RJ, Salant DJ. Experimental membranous nephropathy redux. Am J Physiol Renal Physiol. 2005; 289: F660-71
|
|
|
|
|
|
9) Nangaku M, Couser WG. Mechanism of immune-deposit formation and the mechanism of immune injury. Clin Exp Nephrol. 2005; 9: 183-9
|
|
|
|
|
|
10) Takeda S, Kida H, Katagiri M, et al. Characteristics of glomerular lesions in hepatitis B virus infection. Am J Kidney Dis. 1988; 24: 57-62
|
|
|
|
|
|
11) Floege J, Johnson RJ, Gordon K, et al. Altered glomerular extracellular matrix synthesis in experimental membranous nephropathy. Kidney Int. 1992; 42: 573-85
|
|
|
|
|
|
12) Lundgren S, Carling T, Hjalm G, et al. Tissue distribution of human gp330/megalin, a putative Ca2＋-sensing protein. J Histochem Cytochem. 1997; 45: 383-92
|
|
|
|
|
|
13) Kerjaschki D. Pathogenetic concepts of membranous glomerulopathy (MGN). J Nephrol. 2000; 13 Suppl 3: S96-100
|
|
|
|
|
|
14) Debiec H, Guigonis V, Mougenot B, et al. Antenatal membranous glomerulonephritis due to anti-neutral endopeptidase antibodies. N Engl J Med. 2002; 346: 2053-60
|
|
|
|
|
|
15) Debiec H, Nauta J, Coulet F, et al. Role of truncating mutations in MME gene in fetomaternal alloimmunisation and antenatal glomerulopathies. Lancet. 2004; 364: 1252-9
|
|
|
|
|
|
16) Nortier JL, Debiec H, Tournay Y, et al. Neonatal disease in neutral endpeptidase alloimmunization: lessons for immunological monitoring. Pediatri Nephrol. 2006; 21: 1399-405
|
|
|
|
|
|
17) Rose NR, Bona C. Defining criteria for autoimmune diseases (Witebsky's postulates revisited). Immunol Today. 1993; 14: 426-30
|
|
|
|
|
|
18) Glassock RJ. Human idiopathic membranous nephropathy―A mystery solved？ N Engl J Med. 2009; 361: 81-3
|
|
|
|
|
|
19) Wakui H, Imai H, Komatsuda A, et al. Circulating antibodies against alpha-enolase in patients with primary membranous nephropathy (MN). Clin Exp Immunol. 1999; 118: 445-50
|
|
|
|
|
|
20) Doi T, Kanatsu K, Nagai H, et al. Demonstration of C3d deposits in membranous nephropathy. Nephron. 1984; 37: 232-5
|
|
|
|
|
|
21) Imai H, Hamai K, Komatsuda A, et al. IgG subclasses in patients with membranoproliferative glomerulonephritis, membranous nephropathy, and lupus nephritis. Kidney Int. 1997; 51: 270-6
|
|
|
|
|
|
22) Ohtani H, Wakui H, Komatsuda A, et al. Distribution of glomerular IgG subclass deposits in malignancy-associated membranous nephropathy. Nephrol Dial Transplant. 2004; 19: 574-9
|
|
|
|
|
|
23) Kuroki A, Iyoda M, Shibata T, Sugisaki T. Th2 cytokines increase and stimulate B cells to produce IgG4 in idiopathic membranous nephropathy. Kidney Int. 2005; 68: 302-10
|
|
|
|
|
|
24) Rahimi S, Qian Z, Layton J, et al. Non-complement-and complement-activating antibodies synergize to cause rejection of cardiac allograft. Am J Transplant. 2004; 4: 326-34
|
|
|
|
|